Status:
COMPLETED
Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
Lead Sponsor:
Novartis Vaccines
Conditions:
Rabies Post-exposure Prophylaxis
Eligibility:
All Genders
10-60 years
Phase:
PHASE3
Brief Summary
Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
Eligibility Criteria
Inclusion
- male and female healthy subjects aged 10-60 years old
Exclusion
- history of rabies immunization
- previous exposure to a suspect rabid animal within the last 12 months
- any significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the past 7 days
- treatment with corticosteroids, immunosuppressive or anti-malaria drugs during the two month period before enrollment
- known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder
- known hypersensitivity to neomycin, tetracycline, amphotericin-B, or any other vaccine component
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
630 Patients enrolled
Trial Details
Trial ID
NCT00345319
Start Date
March 1 2006
End Date
May 1 2006
Last Update
December 14 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Danyang CDC
Danyang, Jiangsu, China